Pfizer announces successful trial of Prevnar 13 vaccine; GLOBO provides transcreative services

October 18, 2012   -   Posted by Admin

Pfizer, Inc., the world's largest pharmaceutical company, has recently announced a successful late-stage trial of Prevnar 13 to protect adults aged 18-49 against pneumococcal bacteria, the cause of infections including pneumonia and meningitis. The vaccine, which generates $3.5 billion in annual sales, already protects those over age 50 and under age 5. GLOBO is Pfizer's translation and transcreation partner for the Prevnar 13 product team, helping them reach out to non-English speaking consumers nationwide. GLOBO professionals provide translation, cultural consulting and transcreative services for the Prevnar 13 website, print material, mobile text schedule program and more for the Spanish-speaking market. GLOBO’s well-developed, proven process produced linguistic accuracy as well as cultural correctness. As globalization fuels the growth of the language services market, GLOBO takes pride in leading the industry with our full-service language and cultural solutions.

About GLOBO Language Solutions, LLC

GLOBO is a full-service language and cultural communications service provider, offering a unique platform that provides users with the ability to communicate on-demand, 24/7, in over 200 languages, via phone, video or text. GLOBO’s complete portfolio of services includes global multicultural marketing and social media communication services, translation, localization, transcreation, on-demand telephone interpreters, on-demand web video interpreters, on-demand short email and chat translation, face-to-face interpreters, foreign language call center services, cultural consulting and marketing research. For more information, please visit the company’s web site:

Additional Resources